Healthcare Investing

Challenge Our client, a UK-based private equity company, was evaluating an investment in a full service global medical communications agency with a portfolio of blue-chip biopharma clients, and as...

Challenge: A new venture fund reached out to Alacrita for support with identifying novel pharma assets available for in-licensing, for the purpose of founding a new start-up and enabling the further...

Challenge Our client, a PE-backed specialty pharma company growing rapidly through M&A, was assessing a number of late-stage development projects to license/acquire. The company was considering a...

Challenge A major VC fund asked Alacrita to conduct a clinical due diligence on a potential investment in a company targeting CNS indications. The target company was led by an executive with whom the...

Challenge: An investor and asset manager was considering an investment in a European biotech company with one development product for hemophilia and another approved OTC product in an unrelated...

Challenge: An innovation fund interested in a research institute developing proprietary mAbs against a novel liver disease target, asked Alacrita to conduct due diligence on the development of this...

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...

Challenge: A VC firm was exploring investment in a spin-out company with an antibody targeted at metastatic cancer indications. Before committing to the financing round, the investor required...

Challenge: A private investment firm was interested in a European drug re-purposing company and asked Alacrita to perform top-level due diligence to help the firm decide whether it wanted to proceed...

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...

Challenge A company considering an investment in a new early-stage biosensor technology for the measurement of blood pressure needed due diligence support. The product had a number of potential...